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Abstract
Rationale: A prolonged, prodromal phase before deﬁnitive paediatric precursor B acute lymphoblastic leukaemia (BCP ALL)
diagnosis is rarely observed.
Patients concerns: In the ﬁrst, the patient presented with an aplastic preleukemic phase, whilst the second presented with a
rheumatic-like preliminary phase.
Diagnoses: The case reports of two patients with BCP ALL with a prodromal phase lasting a few weeks are presented.
Interventionsandoutcomes:DNAwhole genomeproﬁlemethylation analysis of bonemarrowcells obtained at diagnosis revealed
a pattern of methylation that was readily distinguishable from both healthy and standard course BCP ALL bone marrow samples.
Lessons: The biological implication of this observation remains unclear, with many differentially methylated loci involved in many
processes like neurogenesis, cell projection organization and adhesion along with leucocyte activation and apoptosis. The
prevalence and clinical signiﬁcance of these methylation changes is unknown but this data indicates that the epigenetic basis of BCP
ALL with a prolonged, prodromal phase requires a more detailed assessment.
Abbreviations: ALL = acute lymphoblastic leukemia, BM = bone marrow, CBC = complete blood count, DM = differentially
methylated, ESR = erythrocyte sedimentation rate, PLT = platelet count, PP = prodromal phase, SC = standard course, WBC =
white blood cells.
Keywords: BCP ALL, DNA methylation, pediatric, 2 cases
1. Introduction
Acute lymphoblastic leukaemia (ALL) onset is usually sudden
with a short history. A prolonged, prodromal phase (PP) before
deﬁnitive ALL diagnosis is rarely observed. ALL can be
recognized by bone marrow (BM) biopsy/aspirate and/or
peripheral blood smear examination. WHO criteria from
2008[1] state that to establish a diagnosis of ALL, more than
20% to 25% of the lymphoblasts in bone marrow (BM) must
possess a diagnostic phenotype. In the unusual case, that a patient
presents with fewer than 20% lymphoblasts in the BM and with
no evidence of an extramedullary mass but demonstrates 1 of the
known recurring cytogenetic abnormalities associated with ALL,
the patient may be considered to have lymphoblastic leukaemia.
The observation of fewer than 20% unequivocal lymphoblasts in
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the BM should, however, also prompt a search for lymphoblastic
lymphoma in an extramedullary location.[2,3]
Leukaemia initiation requires nucleotide sequence changes to
occur, such as point mutations, ampliﬁcations or chromosome
translocations. In concert with these genetic changes, disrupted
epigenetic regulation (via DNA methylation, post-translational
histone modiﬁcations, and interaction with non-coding RNA
(miRNA or siRNA)) results in the abnormal expression of key
genes responsible for cell proliferation and differentiation.[4]
The most common clinical symptoms of ALL in children are
secondary to peripheral pancytopenia resulting from normal BM
precursor displacement. Sometimes a clinical view is comple-
mented by hepatosplenomegaly, lymphadenopathy, symptoms of
the central nervous system, or testis involvement, persistent fever,
weight-loss and bone pain (particularly limb pain). Usually,
examination of BM aspirates reveals up to 70% to 100%
undifferentiated cells which correspond to the lymphoblast
precursors, making ALL diagnosis proven. Deﬁnitive diagnosis of
ALL thus normally takes no more than 2-3 weeks from the time
of the ﬁrst symptoms presenting.
In our previous work, hierarchical clustering of whole-genome
DNA methylation proﬁles obtained from BM cells aspirated at
diagnosis of a group of 38 patients with pediatric B-cell precursor
(BCP) ALL revealed 2 cases with noticeably different methylation
proﬁles.[5] Detailed clinical analysis of these patients showed that
both had preceding clinical symptoms of leukaemia many weeks
beforeALLdiagnosiswas established. This pre-leukemic phasewith
incomplete features was misleading and delayed treatment. Herein
we present the case reports of these 2 children.We, therefore, sought
to fully analyze the differences in CpG methylation sites between
BCPALL patients with the standard course (SC) (BCPALL SC) and
the 2 with incomplete feature PP (BCP ALL PP).
2. Materials and methods
2.1. Ethical statement
Ethics Committee approval was obtained from the Institutional
Review Board of the Medical University of Lodz (number, RNN/
226/11/KE). Informed consent has been obtained from parents/
legal guardians of all the participating children. Furthermore
informed written consent was obtained from the parents of the 2
patients presented in this case report for publication. The study
protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki.
2.2. Whole genome DNA methylation proﬁle analysis
In our previous study[5] material comprised 38 samples of BM
obtained from patients with pediatric precursor-B acute
lymphoblastic leukaemia, at the time of the ﬁnal ALL diagnosis,
and 4 control non-leukemic samples. The analysis of cytogenetic
ALL subtypes revealed that among BCP ALL SC patients there
were 2 cases of triploidy and 12 cases of hyperploidy which might
serve as a control for the analyzed BCP ALL PP patients. The
previous results also showed, that factors such as gender and age
are not important confounders for the global methylation proﬁle
differentiation of pediatric leukaemia.[5] DNA was puriﬁed using
QIAamp DNA Blood Mini Kit (QIAGEN), assessed for
fragmentation by agarose gel electrophoresis and quantiﬁed
using Qubit 2.0 ﬂuorimeter (Thermo Fisher Scientiﬁc). CpG
methylation analysis was performed using Illumina (San Diego,
CA)MethylationEPIC BeadChip, allowing analysis of 850K sites
per sample.
2.3. Data quality control and analysis
The raw intensity data were checked for quality using the
BeadArray Controls Reporter software (Illumina) and analyzed
using the ChAMP package pipeline.[7] First, probes with
detection of P value <.01 and with fewer than 3 beads in at
least 5% of samples per probe were excluded. Additionally, non-
CpG probes, SNP-related probes, multi-hit probes and probes
located on chromosome X and Y were also removed. Then, the
beta values (the proportion of DNA methylation at a CpG site)
for 753,390 sites were calculated and assessed for quality by
evaluation of beta multidimensional scaling (MDS) and density
plots across the study groups. A beta value of 0 represents a
completely unmethylated CpG site and a beta value approaching
1 represents a fully methylated CpG site. Beta values were
normalized using the BMIQ method.[8] Singular value decompo-
sition (SVD)[9] was used to identify the most signiﬁcant
components of variation, including technical variation. Differen-
tial methylation analysis between groups was performed using
the champ.(DMP) function which implements the limma
package[10] to calculate the P value for differential methylation
using a linear model. The obtained p-values were corrected for
multiple testing using the Benjamini–Hochberg procedure.[11]
2.4. Functional genes annotation and analysis
The genes associated with speciﬁc differentially methylated (DM)
sites were separated depending on CpG site location (promoter,
gene body) and analyzed in terms of molecular functions,
biological presses, cellular components, pathways and phenotypes
using WebGestalt (WEB-based GEne SeT AnaLysis) toolkit,[12]
exploiting information obtained fromGO,KEGG,WikiPathways,
Human Phenotype Ontology and PharmGKB databases. Over-
representation tests were performed with respect to all known
human genes (genome), identifying enriched categories with a
corrected P value (false discovery rate [FDR]) lower than 0.05 and
requiring at least 5 genes per enriched category.
2.5. Methylation assay performance and differential
methylation analysis
The assay performance, as evaluated based on control probes and
BeadArray Controls Reporter software, was satisfactory across
all studied samples. After preliminary ﬁltering, 753,390 probes
beta values were normalized and the batch effect was evaluated
using the SWD method.
The comparison of methylation level of 753,390 sites between
the 2 caseswithBCPALLPPandBCPALLSC samples allowed the
identiﬁcation of 11,854DMCpGs (adj P< .05). Of the sites, 7239
were hypermethylated in cases with PP ALL with an average delta
beta between groups of 0.224 (±0.109). The remaining 4615 sites
were hypomethylated with a slightly lower absolute delta beta
value of 0.170 (±0.071). Both hyper- and hypomethylated CpGs
were distributed on all 22 autosomes and the number of CpG per
chromosome ranged from 1203 on HSA1 to 145 on HSA21.
CpG context analysis showed that 2090 of DM sites were
located in gene promoter regions (TSS200 and TSS1500), 1433 in
genes 50-UTR or ﬁrst exon and 4770 within gene bodies. Most of
the detected DM sites (7302; 61.6%) were located outside known
CpG islands and remaining ones were positioned in islands
(18.3%) or islands’ shelves and shores (20.1%). The detailed
analysis of distribution of hyper- andhypomethylated sites showed
that hypermethylation in BCP ALL PP is more common within
promoter regions (22.7% versus 9.7% of all DM CpGs) and
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known CpG islands (27.9% versus 3.2%) whereas hypomethy-
lation occurs more frequently in gene bodies (48.4% versus 35.0)
and regions outside islands (open sea; 78.8 versus 50.6%). DM
sites and their annotations are reported in Supplementary File 1,
http://links.lww.com/MD/C552.
Hypothesizing that some of the sites DM between BCP ALL PP
and BCPALL SCmay conform to the methylation proﬁle found in
healthy BM samples, an additional comparison was made with
respect to control samples. This analysis allowed the identiﬁcation
41,952 DM sites of which 1511 overlapped with sites differing
with respect to BCP ALL SC (Supplementary File 2, http://links.
lww.com/MD/C553). Most of these sites were hypermethylated
with respect to the control (1094; 72.4%) with an average delta
beta of 0.228. Most of the sites were also hypermethylated with
respect to BCP ALL SC with samples (1008) with average delta
beta of 0.234. The selected DM sites were scattered across all
autosomes with the highest number located on the biggest
chromosomes and in gene bodies (35.8%), intergenic regions
(24.9%), and outside known CpG islands (50.6%).
Unsupervisedhierarchical clusteringof the samplesbasedonprobes
differingbetweenBCPALLPPandbothALLBCPSCand the control
samples shows a clear separation of the 2 BCP ALL PP methylation
proﬁles from both remaining groups with higher similarity to BCP
ALL SC cases (Fig. 1). Comparable results were obtained when
principal component analysis (PCA) was applied to the same probes
(Fig. 2). For further gene functions analysis, only CpGs differing in
methylation level between BCP ALL SC and control were used. 0
3. Results
3.1. Patient 1
This patient is a 10-year-old male with a history of the growth
hormone deﬁciency, at admission he was undergoing growth
hormone supplementation therapy. The patient was initially
referred to hematology due to abnormal complete blood count
(CBC) values (initial values: hemoglobin (Hb) of 9.6g/dL,
leukocytes (WBC) of 0.69109/L, neutrophils of 0.1109/L,
and a platelet count (PLT) of 121109/L.). Examination of
peripheral blood smears revealed no blast cells. For 2weeks before
admission, the patient presented with a refractory fever of up to
39°Cdespite receiving 10-days axetil cefuroxime.At admission, no
clinical and laboratory signs of infection were presented
(procalcitonin, CRP, erythrocyte sedimentation rate (ESR) were
among normal range) except for a urine culture which revealed
Morganella morganii species 106/mL. Physical examination,
conﬁrmed by imaging, revealed hepatomegaly (liver AP diameter
up to 12cm) without any other abnormalities. Piperacillin with
tazobactam therapy was introduced with a good clinical response.
There was a resolution of the fever and the urine culture became
sterile. Despite this, CBC values remained abnormal.
With a presumptive diagnosis of leukaemia, after admission, BM
aspirates were obtained for morphology, immunophenotype, and
cytogenetic analysis. Morphologically the BM was hypocellular
with a paucity of megakaryocytes, abnormal granulopoiesis, and
containingup to20%ofblasts.The immunophenotyping revealed2
populations. The ﬁrst population of CD34+/CD19+ cells with co-
expression of myeloid antigen CD66+ (80% cells from this
population) representing 2,5% of the total nucleated cells. The
second population of CD34-/CD19+ also with CD66+ (60% cells)
represented up to 20% of the total nucleated cells. The BM biopsies
were repeated4 times every fewdays, but theBMsmears picturewas
constantly hypocellular with lymphoblast percentage within the
range of 10% to 25%. A similar percentage of lymphoblasts were
observedby trephine biopsy examination,which revealedﬁeldswith
different lymphoblast content.More than3weeks after admission, a
spontaneous increase of white blood cells (WBC 2.64109/L) and
platelets (PLT 363109/L) in the peripheral blood was observed
with domination of lymphocytes (69%) but still without undiffer-
entiated cells in the peripheral blood smears. After a further 2weeks
(about 5 weeks after admission) BM aspiration revealed the typical
picture of acute leukaemia with hypercellular BM. The total
percentage of blasts was about 35% with phenotype CD34-,
CD19+, CD10+, CD22+, CD52+, CD38+, HLA-DR+ with co-
expression CD66+ (55% cells), and CD15+ (60% cells). Conven-
tional cytogenetic analysis by G-banding revealed the presence of
additional chromosomes 4, 6, 17, 18, 21, and excluded the crucial
aberrations connected with BCR/ABL or MLL loci.
Finally, the diagnosis of BCP ALL was established about 7 to 8
weeks after the onset of ﬁrst symptoms. The treatment according
to ALL IC BFM 2009 protocol[6] for an intermediate risk group
without central nervous system involvement was introduced. A
good prednisone response was observed and he achieved
haematological remission on the ﬁfteenth day with minimal
residual disease level 1.8105. Presently, the maintenance oral
chemotherapy is being continued and the patient has stayed in
complete remission for 22 months.
3.2. Patient 2
This patient is a 6-year-old male was presented to rheumatology
unit with a 5 months history of bone pain in both legs. Irregular
episodes of fever up to 39°C (with frequency once a week) with
spontaneous remission began 1 month after the onset of the bone
pains. A systemic connective tissue disease was suspected.
Comprehensive diagnostics was implemented. Initial CBC includ-
edHbof 11.7g/dL, leukocytes (WBC) of 6.22109/L, neutrophils
of 1.95109/L, and a PLT of 550109/L. A peripheral blood
smear revealed a slightly increased percentage of lymphocytes
(66%) and monocytes (10%) with the presence of atypical
lymphoid cells (2%). The levels of CRP protein and ferritin as ESR
were increased reﬂecting the active inﬂammatory process.
Unfortunately, BM aspiration during this prodromal symptom
phase was not performed, so BM cellularity and blast cells
percentage before establishing the formal diagnosis is unknown.
Three weeks later, after the exclusion of rheumatic disorders,
the patient was referred to haematology with persistent clinical
symptoms and stable values of CBC, CRP, ferritin, and ESR.
Physical examination revealed no symptoms of infection, no
lymphadenopathy or hepatosplenomegaly, the neurological
status, skin and testes were normal. Manual examination of
peripheral blood smear revealed the presence of undifferentiated
cells (5%) therefore a BM aspiration was performed. Immuno-
phenotypic analysis of the BM aspirates revealed 61% of
precursor B lymphoblasts with the coexpression of the myeloid
line (about 1/3 cells with CD33+). Genetic analysis of blasts
revealed the presence of a complex karyotype with hypotriploidy
(63∼66 chromosomes), with rearrangements loci IGH and
TCRAD. Due to traumatic lumbar puncture, the central nervous
system status stayed unknown. Finally, the diagnosis of BCP ALL
was established, and the patient was stratiﬁed to the intermediate
risk group according to ALL IC BFM 2009 protocol.[6] A good
prednisone response was observed and haematological remission
on the ﬁfteenth day with residual minimal disease 7,1103 was
achieved. Presently the patient has been in complete remission for
38 months after diagnosis without BM transplantation.
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4. Discussion
During our study of whole genome methylation changes within
leukaemia methylation pattern across genome showed visible
separation of the 2 samples proﬁles with clear differences with
respect to control and BCP ALL SC patient groups. Detailed
phenotypic analysis showed that these samples were obtained
from cases of BCP ALL with few weeks duration PP before the
conﬁrmation of a formal diagnosis according to the WHO
criteria. The ﬁrst patient presented with an aplastic preleukemic
phase, the second one with rheumatic-like preliminary phase. In
both cases, treatment was delayed until the WHO criteria were
fulﬁlled, so the “watch and wait” strategy was implemented. The
Figure 1. Hierarchical clustering of samples and methylation heatmap according to probes differing in methylation level between BCP ALL PP and both BCP ALL
with the standard course (BCP ALL SC) and control samples.[5] BCP ALL PP=B-cell precursor acute lymphoblastic leukaemia with incomplete feature prodromal
phase, SC=standard course.
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potential acceleration of leukaemia with its serious complications
can be a reason for some concern for both patients and
practitioners.
Aplastic PPs are rare but well recognized in childhood BCP
ALL.[13–15] This neoplasm usually develops via a minimum of 2
discrete stages. First, the acquisition of chromosomal abnormali-
ties (e.g., ETV6-RUNX1 fusion, high hyperdiploidy) predomi-
nantly (but not exclusively) during fetal hemopoiesis which drives
the expansion of a clinically silent, or covert, but persistent
preleukemic clone. Second, in a relatively small fraction of such
cases, the accrual, postnatally of further, secondary genetic
changes promote or precipitates disclosure of clinical leukae-
mia.[13,16,17] Occasionally, this form of ALL is initiated by
infection, explaining the long-lasting remission due to induced,
signiﬁcant endogenous corticosteroids production.[6] The fre-
quency of BCP ALLwith preleukemic phase is low, and up to 2%
of the ALL cases can be included in this group[14,18–20] while full
symptomatic ALL appears after a sudden recuperation of the
CBC, with 95% of cases progressing to ALL within 6 months of
initial diagnosis.[21]
Musculoskeletal complaints that depend upon lymphoblast
expansion in BM cavities may be the initial dominating
symptoms of newly diagnosed leukaemia as well as rheumatic
diseases, for example, juvenile idiopathic arthritis. It is extremely
rare, however, to diagnose ALL in children with such complaints
who were originally referred to a pediatric rheumatology unit
(<1% of the all cases).[22–25] In these cases, the mean time
between symptom onset and ﬁnal diagnosis of leukaemia is about
3 months.[23]
The DM sites between BCP ALL PP and both BCP ALL SC and
control samples were associated with 816 different genes. The
genes were enriched in many GO biological processes which were
summarizedwith the software package Revigo[26] to allow for the
detection of their major categories (Table 1). Among the major
classes of enriched biological processes are those associated, for
example, with neurogenesis, cell projection organization and
adhesion but also leukocyte activation and apoptosis.
The analyzed genes are also enriched in several KEGG
pathways. Notably, these include T or B cell receptor signalling
pathways, endometrial cancer or non-small cell lung cancer
Figure 2. Principal component analysis based on probes differing in methylation level between B-cell precursor acute lymphoblastic leukaemia with incomplete
feature prodromal phase (BCP ALL PP) and both BCP ALL with the standard course (BCP ALL SC) and control samples.[5] BCP ALL PP=B-cell precursor acute
lymphoblastic leukaemia with incomplete feature prodromal phase, SC=standard course.
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(Table 2). The disease phenotypes enriched by the genes
include acute myeloid leukaemia and Wiskott-Aldrich syndrome
(Table 3).
Detailed analysis of the genes associated with the probes with
the most signiﬁcant differences in methylation level between BCP
ALL PP and BCP ALL SC allowed the detection of 3 genes
previously associated with the B cell phenotype, leukaemia or
general tumour suppression and included: ENPP1, TCFL5, and
LRRC3B genes.[27–29] The DM sites associated withENPP1 gene
were mainly located in the promoter region (TSS200) and were
predominantly hypermethylated. ForTCFL5 gene, the single DM
sites were situated in TSS1500 (hypomethylated) and 1st exon
(hypermethylated). In the case of the LRRC3B gene, the
hypermethylated sites were distributed across the whole gene
and were annotated to TSS200, 1st exon and 5’UTR.
Togainabetter insight into theaffectedprocesses, thegene listwas
subdivided into 2 categories depending on the location of the probe
within the gene body or promoter region (TSS200, TSS1500) as
methylation in these areas may have opposite effect on the genes’
expression. We identiﬁed 336 probes associated with the promoter
Table 1
Major classes of biological processes enriched by genes with differentially methylated probes.
Term ID Description log10 P value
GO:0022008 Neurogenesis 10.5784
GO:0030030 cell projection organization 8.3665
GO:0006928 movement of cell or subcellular component 7.5498
GO:0040011 Locomotion 6.9318
GO:0043085 positive regulation of catalytic activity 6.4841
GO:0022610 biological adhesion 6.3605
GO:0007155 cell adhesion 6.1739
GO:0046834 lipid phosphorylation 5.7399
GO:0007267 cell-cell signaling 5.7055
GO:0006357 regulation of transcription from RNA polymerase II promoter 5.3449
GO:0001775 cell activation 5.266
GO:0032970 regulation of actin ﬁlament-based process 5.1361
GO:0048870 cell motility 5.1163
GO:0051674 localization of cell 5.1163
GO:0040007 Growth 4.6968
GO:0009611 response to wounding 4.5482
GO:0006915 apoptotic process 4.4461
GO:0030029 actin ﬁlament-based process 4.4202
GO:0008283 cell proliferation 4.2161
GO:0018212 peptidyl-tyrosine modiﬁcation 3.9072
GO:0045321 leukocyte activation 3.8081
GO:0016192 vesicle-mediated transport 3.4564
GO:0014065 phosphatidylinositol 3-kinase signaling 3.4381
GO:0044708 single-organism behavior 3.2898
GO:0034332 adherens junction organization 3.2697
GO:0035411 catenin import into nucleus 3.2696
GO:0006897 Endocytosis 3.1125
Major classes of biological processes enriched by genes with differentially methylated probes between B-cell precursor acute lymphoblastic leukemia with incomplete feature prodromal phase (BCP ALL PP) and
both BCP ALL with the standard course (BCP ALL SC) and control samples. The numerous enriched biological processes found with WebGestalt were analyzed with Revigo system to summarize them by removing
redundant GO terms.
Table 2
KEGG pathways enriched by genes with differentially methylated probes.
FDR Involved genes
T cell receptor signaling pathway 0.000855 AKT3; MAP3K8; FYN; GRB2; LCK; NFATC1; NFATC2; PIK3CG; PIK3R2; PPP3R1; MAP2K1; VAV1; ZAP70; NCK2;
CD28; GRAP2
Phospholipase D signaling pathway 0.006788 AKT3; RAPGEF4; DGKG; DGKH; DGKQ; DNM1; DNM2; FYN; GAB1; GRB2; CXCR2; PIK3CG; PIK3R2; MAP2K1;
DGKZ; DGKD; CYTH1
Cholinergic synapse) 0.010435 AKT3; CHRM2; CHRNB4; FYN; GNGT2; KCNQ2; ACHE; PIK3CG; PIK3R2; PRKCG; MAP2K1; CREB3L2; CACNA1C;
CAMK4
Endometrial cancer 0.012396 AKT3; ERBB2; GRB2; PIK3CG; PIK3R2; MAP2K1; TCF7; TCF7L1; CDH1
Non-small cell lung cancer 0.017792 AKT3; ERBB2; GRB2; PIK3CG; PIK3R2; PRKCG; MAP2K1; RXRA; TGFA
Phosphatidylinositol signaling system 0.020693 DGKG; DGKH; DGKQ; INPP1; INPP4A; INPP5A; PIK3CG; PIK3R2; PLCD1; PRKCG; DGKZ; DGKD
B cell receptor signaling pathway 0.020693 AKT3; GRB2; BLNK; NFATC1; NFATC2; PIK3CG; PIK3R2; PPP3R1; MAP2K1; VAV1
Adherens junction 0.020693 ERBB2; FER; FYN; SMAD3; NLK; TCF7; VCL; TCF7L1; ACTN1; CDH1
ErbB signaling pathway 0.020693 AKT3; ERBB2; GAB1; GRB2; PIK3CG; PIK3R2; PRKCG; MAP2K1; TGFA; NCK2; NRG2
Top 10 KEGG pathways enriched by genes with differentially methylated probes between B-cell precursor acute lymphoblastic leukemia with incomplete feature prodromal phase (BCP ALL PP) and both BCP ALL
with the standard course (BCP ALL SC) and control.
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regions of 214 different genes. These genes did not enrich any of the
GO biological processes, phenotypes or pathways. Analysis of the
445 genes associated with probes located in gene bodies was found
to be enriched in a wide range of biological processes that could be
reduced to major categories and are related to processes such as
regulation of GTPase activity, positive regulation of cell communi-
cation or apoptotic processes (Table 4).
The genes with observed methylation differences within the
gene bodies also enriched KEGG pathways associated with inter
alia: non-small cell lung cancer, B cell receptor signalling
pathway, endometrial cancer, renal cell carcinoma, and prostate
cancer (Table 5). The diseases enriched by the genes included 3
phenotypes, namely: neoplastic cell transformation, adhesion
aberration and Wiskott–Aldrich syndrome.
Kulis et al postulate that changes shared during neoplastic
transformation and normal differentiation of lymphocytes B may
represent epigenetic passengers whereas those exclusively taking
place in tumour cells should contain epigenetic drivers with a
potential functional impact in the disease.[30] The prevalence and
clinical signiﬁcance of the observed methylation changes,
however, cannot be discerned from 2 patients alone. It is
possible, however, to distinguish some differences in the DNA
methylation proﬁle between patients with BCP ALL PP and BCP
ALL SC or individuals from the control group. No methylation
changes were identiﬁable that could be obvious epigenetic drivers
in these cases.
The frequency and implications of these methylation changes
cannot be answered herein. Our data indicates, however, that the
epigenetic basis of BCP ALL with an incomplete, prolonged, PP
requires amoredetailedassessmentwith a larger numberofpatients.
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Table 3
Disease phenotypes enriched by genes with differentially methylated probes.
FDR Involved genes
Adhesion 0.002432 CDH4; CD96; EFNA5; SDK1; FER; ITGA11; ARHGAP26; FYN; CADM2; RGMB; GRB2; ICAM3; ITGA6; ITGAE; ITGAL;
ITGB1; LAMB1; LIMS1; MGAT5; MYH9; NEO1; NRCAM; OLR1; PIK3CG; APBB1IP; STAB2; RADIL; PRKCE;
PCDHGA4; PCDHA6; PCDHA2; RDX; RAPH1; SLC3A2; SVIL; TGFBI; TRIO; VCL; DDR1; NCK2; ACTN1; ARHGEF7;
STARD13; CLDN10; CYTH1; NRXN2; CYTIP; PCDHGA8; CDH1
Drug interaction with drug 0.002432 PDIA5; ADD1; HSPB6; ADORA2A; ERBB2; F3; FYN; GAB1; SIN3A; GRB2; APP; ITGAL; ITGB1; KCNA4; KCNMA1;
LCK; SMAD3; MAP1A; ACHE; PIK3CG; PIK3R2; PRKCE; PRKCZ; MAP2K1; RDX; RXRA; RYR2; S100A8; VAV1;
ACTN1; ARHGEF7; ABCG2; BAG3; NCOR2
Leukemia, Myeloid, Acute 0.009786 CD96; MSI2; CSF3R; CUX1; DNMT3A; ETV6; ARHGAP26; SIN3A; GATA2; IRF8; MIR155; MPO; PBX1; MKL1;
PRDM16; SECTM1; ZBTB16; ZNF496; ABCG2; BRE; NCOR2; CDA
Ventricular Fibrillation 0.028874 DPP6; KCNE1; KCNK3; RYR2; CACNA1C; CACNA2D1; EFCAB1; TANC1; KCNH7; NOS1AP
Wiskott-Aldrich Syndrome 0.044225 ABI2; WHAMM; DNM1; DNM2; FYN; GRB2; ITSN2; AMBRA1; ITSN1; NCK2; ARHGEF7; MTSS1L; MTSS1
Developmental disorder NOS 0.049191 DNM1; DYRK1A; AUTS2; FOXP1; HADHB; APP; KCNQ2; MAPT; MARK1; CHD7; MAP2K1; ARID1B; DCDC2C; NUAK1
Disease phenotypes enriched by genes with differentially methylated probes between B-cell precursor acute lymphoblastic leukemia with incomplete feature prodromal phase (BCP ALL PP) and both BCP ALL with
the standard course (BCP ALL SC) and control samples.
Table 4
Major classes of biological processes enriched by genes with differentially methylated probes located within gene bodies.
Description log10 P value
GO:0043087 regulation of GTPase activity 7.5784
GO:0010647 positive regulation of cell communication 6.0232
GO:0046834 lipid phosphorylation 4.9747
GO:0030032 lamellipodium assembly 4.7773
GO:0034330 cell junction organization 4.7696
GO:0016192 vesicle-mediated transport 4.382
GO:0032970 regulation of actin ﬁlament-based process 4.2581
GO:0045216 cell-cell junction organization 4.251
GO:0022603 regulation of anatomical structure morphogenesis 4.2248
GO:0040011 Locomotion 3.7327
GO:0007009 plasma membrane organization 3.7188
GO:0006915 apoptotic process 3.7024
Major classes of biological processes enriched by genes with differentially methylated probes located within gene bodies between B-cell precursor acute lymphoblastic leukemia with incomplete feature prodromal
phase (BCP ALL PP) and both BCP ALL with the standard course (BCP ALL SC) and control samples. The numerous enriched biological processes found with WebGestalt were analyzed with Revigo to summarize
them by removing redundant GO terms.
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